Figure 6. Prognostic value of the risk signature in patients stratified by WHO grade. (A–C) Kaplan–Meier overall survival curves for patients with WHO grade II (A), WHO grade III (B), and GBM (C). (D-E) ROC curves showed the predictive efficiency of the risk signature on mesenchymal subtype in GBM of CGGA (D) and TCGA (E) datasets. (F-I) GBM patients with high risk scores had a greater benefit from TMZ chemotherapy.